For instance, the CXCR2 antagonist, SCH-527123, was able to decrease phosphorylation of NF-κB in colorectal cancer cells [34] while in ovarian cancer cells, CXCR2 stimulated angiogenesis by a process thought to also involve NF-κB [9]. Here, NFKB1 is linked to ovarian carcinoma.